Zoomcar Holdings, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Zoomcar Holdings, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $9.11M | Jun 30, 2025 |
| FY2025 | Mar 31, 2024 | $9.90M | Jun 30, 2025 |
| FY2024 | Mar 31, 2023 | $8.83M | Jul 15, 2024 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Mar 31, 2024 | $9.90M | Jul 15, 2024 |
| FY2024 | Mar 31, 2023 | $8.83M | Jul 15, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($25.62M) | Jun 30, 2025 |
| FY2025 | Mar 31, 2024 | ($34.28M) | Jun 30, 2025 |
| FY2024 | Mar 31, 2023 | ($62.03M) | Jul 15, 2024 |
| FY2022 | Dec 31, 2022 | ($4.63M) | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | ($229.2K) | Mar 31, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($10.40M) | Jun 30, 2025 |
| FY2025 | Mar 31, 2024 | ($31.67M) | Jun 30, 2025 |
| FY2024 | Mar 31, 2023 | ($36.46M) | Jul 15, 2024 |
| FY2022 | Dec 31, 2022 | ($8.01M) | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | ($233.3K) | Mar 31, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $2.97M | Jun 30, 2025 |
| FY2025 | Mar 31, 2024 | $4.35M | Jun 30, 2025 |
| FY2024 | Mar 31, 2023 | $5.18M | Jul 15, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($9.08M) | Jun 30, 2025 |
| FY2025 | Mar 31, 2024 | ($22.20M) | Jun 30, 2025 |
| FY2024 | Mar 31, 2023 | ($36.27M) | Jul 15, 2024 |
| FY2022 | Dec 31, 2022 | ($1.47M) | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | ($480.5K) | Mar 31, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $5.36M | Jun 30, 2025 |
| FY2025 | Mar 31, 2024 | $9.17M | Jun 30, 2025 |
| FY2024 | Mar 31, 2023 | $16.46M | Jul 15, 2024 |
| FY2022 | Dec 31, 2022 | $238.21M | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $236.01M | Mar 31, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $30.71M | Jun 30, 2025 |
| FY2025 | Mar 31, 2024 | $42.86M | Jun 30, 2025 |
| FY2024 | Mar 31, 2023 | $68.40M | Jul 15, 2024 |
| FY2022 | Dec 31, 2022 | $19.03M | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $12.28M | Mar 31, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($25.35M) | Jun 30, 2025 |
| FY2025 | Mar 31, 2024 | ($33.69M) | Jun 30, 2025 |
| FY2025 | Mar 31, 2023 | ($246.03M) | Jun 30, 2025 |
| FY2022 | Dec 31, 2022 | ($18.81M) | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | ($10.87M) | Mar 31, 2023 |
| FY2022 | Mar 21, 2021 | $0 | Mar 31, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($333.17M) | Jun 30, 2025 |
| FY2025 | Mar 31, 2024 | ($307.55M) | Jun 30, 2025 |
| FY2024 | Mar 31, 2023 | ($270.00M) | Jul 15, 2024 |
| FY2022 | Dec 31, 2022 | ($18.81M) | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | ($10.87M) | Mar 31, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Mar 31, 2024 | $1.50M | Jul 15, 2024 |
| FY2024 | Mar 31, 2023 | $3.69M | Jul 15, 2024 |
| FY2022 | Dec 31, 2022 | $10.4K | Mar 31, 2023 |
| FY2021 | Dec 31, 2021 | $979.6K | Mar 29, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2024 | $2.85M | Jun 30, 2025 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | (51) | Jun 30, 2025 |
| FY2025 | Mar 31, 2024 | (3,839) | Jun 30, 2025 |
| FY2024 | Mar 31, 2023 | (128) | Jul 15, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | (51) | Jun 30, 2025 |
| FY2025 | Mar 31, 2024 | (3,839) | Jun 30, 2025 |
| FY2024 | Mar 31, 2023 | (128) | Jul 15, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 2.46M | Jun 30, 2025 |
| FY2025 | Mar 31, 2024 | 32,160 | Jun 30, 2025 |
| FY2024 | Mar 31, 2023 | 482,681 | Jul 15, 2024 |
| FY2021 | Dec 31, 2021 | 0 | Mar 29, 2022 |